E

Editas Medicine
D

EDIT

2.37500
USD
-0.04
(-1.66%)
Market Closed
Volume
0
EPS
-3
Div Yield
-
P/E
-1
Market Cap
195,881,536
OverviewSignalsIdeasNews
Related Instruments
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    B
    BEAM
    -2.275
    (-8.65%)
    24.035 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    R
    RGEN
    -17.400
    (-12.22%)
    124.960 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    TMO
    TMO
    -19.95
    (-3.74%)
    516.18 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.37 USD
    More
News

Title: Editas Medicine

Sector: Healthcare
Industry: Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.